Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Slovenia

Coordination and Support Action · Running

PRECISON-ECS Precision oncology platform for personalised cannabinoid-based cancer therapies

Coordinator
EndoVia Therapeutics, Slovenia
Runs
1 July 2026 to 30 June 2028
Status
Running
EU funding
€344k
Total cost
—
Partners
1 organisations in 1 countries
Type
Coordination and Support Action
Grant agreement
101310106

What the project is doing

In the project's own words, from its summary on CORDIS.

This project aims to develop and validate a precision oncology platform that predicts individual cancer patients’ responses to cannabinoid-based therapies. Cannabinoids show promising anti-tumour activity, but their clinical use remains limited by inconsistent outcomes, lack of predictive biomarkers, and the absence of tools that identify which patients may benefit. To address this gap, EndoVia Therapeutics will create a digital twin model of melanoma that integrates patient-derived tumour samples, multi-omics profiling of the endocannabinoid system (ECS), and mechanistic, AI-supported simulations of tumour–cannabinoid interactions.

The project will generate biopsy-derived melanoma models, stratified cannabinoid response datasets, and validated ECS biomarkers, which will serve as the biological foundation for training and testing the predictive engine. In vitro and in vivo studies, including patient-derived xenograft mouse models, will be used to refine and confirm the accuracy, safety, and translational relevance of the platform. The resulting preclinical demonstrator (TRL 6) will provide oncologists and drug developers with an evidence-based tool to guide compound selection, identify responders, and inform combination strategies with standard therapies.

In parallel, the project will establish the regulatory, clinical, and commercial pathways needed for future deployment, including a clear IP and FTO strategy, early engagement with clinical experts and industry partners, and a roadmap for IVDR/MDR compliance. By enabling data-driven personalisation of cannabinoid therapies, the project supports the objectives of the Horizon Europe Work Programme to advance precision medicine, accelerate translation of novel therapeutic approaches, and strengthen Europe’s leadership in AI-enabled oncology.

The outcome will position the technology for early clinical validation and follow-on investment, contributing to more effective, personalised, and safer cancer treatment options.

Who is involved

OrganisationCityCountryRole
EndoVia TherapeuticsMariborSloveniaCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI